Abstract. Background (26.6 vs. 19.3 mm, p=0.022). Conclusion: Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.
clinical outcomes among patients within the same risk group. This is particularly true for men with intermediate-risk prostate cancer, where so-called favorable-intermediate prostate cancer behaves similarly to low-risk disease with regards to prostate cancer-specific mortality (PCSM), while unfavorable-intermediate risk more closely follows high-risk disease (2, 3) .
The Memorial Sloan Kettering Cancer Center (MSKCC) model (Table I) proposes to divide the intermediate group into "favorable" and "unfavorable" categories (2) . Men with a biopsy Gleason score (GS) of ≤ 3+4 and less than 50% of biopsy cores positive are classified as having favorable intermediate-risk disease. In contrast, men with a GS ≥ 4+3 and more than 50% of biopsy cores positive, or those with multiple risk factors including PSA 10-20 ng/ml, cT2b-c staging, and a GS of 7, are classified as unfavorable intermediate-risk disease.
The prostate cancer risk stratification (ProCaRS) model (Table I) proposes to divide the intermediate-risk group into high-and low-risk categories (4) . The low intermediate-risk group contains men with T1-T2 disease and PSA <10 ng/ml, or men with stage T1-T2 disease, PSA between 10 and 20 ng/ml, and GS ≤6. The high intermediate-risk group contains men with T2b/c disease or GS 7 with PSA <20 ng/ml. Table  I summarizes the criteria for these two classification systems.
Multiparametric MRI (mpMRI) has shown promise for improving biopsy targeting, staging accuracy, active surveillance program design, image-guidance for treatment delivery, and for predicting adverse pathologic outcomes (5) (6) (7) (8) (9) (10) . However, it is unknown whether mpMRI parameters may be associated with the recently established intermediaterisk sub-stratification models which predict PCSM.
In the present study, we investigated whether unfavorable/ high intermediate-risk or favorable/low groups based on the MSKCC and ProCaRS models in men with intermediate-risk prostate cancer correlate with pre-treatment mpMRI parameters or pathologic specimen information following radical prostatectomy (RP). (11) . The mpMRI procedure acquired multiplanar T2 weighted imaging, diffusion weighted and contrast enhanced imaging. Image interpretation was performed on T2 weighted images. K trans values were obtained from images acquired with intravenous gadolinium contrast. Apparent diffusion coefficient maps were created from diffusion weighted images. Additional imaging details have been previously described (12 Additionally, the apparent diffusion coefficient (ADC), capillary permeability (k trans and k ep ), iAUC, max tumor diameter (MTD), and MRI suspicion (Likert) score of the largest lesion for each patient were recorded from the clinical mpMRI report. In 2012 our institution was not using the PIRADS system. RP specimen data were also collected, including pathologic T-stage, GS, extracapsular extension (ECE), seminal vesicle invasion, lymphovascular invasion, perineural invasion and mean tumor diameter (MTD). The MSKCC and ProCaRS intermediate-risk stratification models were evaluated for their ability to discriminate between both pretreatment mpMRI parameters and adverse pathologic outcomes following RP.
Patients and Methods
Statistical analysis. 2-sample T-tests assuming unequal variance and odds ratios (OR) with 95% confidence intervals (CI) were used to compare sub-group pre-treatment MRI parameters and adverse pathologic outcomes. A p-value <0.05 was considered statistically significant.
Results
Baseline clinical, biopsy, and mpMRI characteristics. Table II describes the patient characteristics. The median age of the patients was 62 years (range 44-78). The mean (±standard deviation, SD) PSA was 7.5 ng/ml (±3.8). 68% of patients had a GS of 3+4, while 32% had a GS of 4+3. The volume of prostate cancer, as measured by evaluating the number (percentage) of biopsy cores positive prior to treatment, the amount of biopsy core positive for malignancy, or the MTD in the pathologic specimen, has been consistently associated with key clinical outcomes in multiple studies. In a cohort of low-and favorable intermediate-risk men treated with definitive radiotherapy, >50% biopsy cores positive was significantly associated with worse PCSM (13) . In another study of more than 1,000 patients with cT1c-T3N0M0 prostate cancer treated with external beam radiotherapy with or without a high-dose-rate brachytherapy boost, the percentage of cores positive was associated with rates of distant metastasis, cause-specific survival, and overall survival (14) . Further reinforcing the prognostic importance of the volume of disease in prostate cancer treated with radiotherapy, the percentage of cancer volume in biopsy cores has been shown to be prognostic for biochemical failure, distant metastasis, cause-specific survival, and overall survival, even in patients treated with dose-escalated external beam radiotherapy (15) .
In the post-prostatectomy setting, it has been demonstrated that men with a MTD >1.4 cm are at an independently increased risk for biochemical failure, distant metastasis, and prostate cancer-specific survival after salvage radiotherapy (16) . In another study, a MTD ≤1.2 cm in the RP specimen showed a low risk of PSA recurrence despite adverse other features being present (17) . Therefore, regardless of the treatment modality (external beam radiotherapy with or without high-dose-rate brachytherapy, dose-escalated external radiotherapy, or radical prostatectomy), prostate cancer volume is undoubtedly an important factor to consider for management and prognosis. Therefore, the association of the MSKCC and ProCaRS models to surrogates of prostate volume, including pathologic MTD (both models), percentage of prostate involved with malignancy (MSKCC model), and to pre-treatment mpMRI MTD in the ProCaRS model, may help inform why these models help stratify for PCSM.
Unfortunately, imaging, even with mpMRI, appears to consistently underestimate the size and extent of prostate tumors. For example, a recent radiologic-pathologic correlation study of over 100 men using modern mpMRI demonstrated that pathologic prostate cancer foci had an average diameter 11 mm longer and a volume three times greater than based on mpMRI prediction (18) . This may account for the reason that in our study, pre-treatment mpMRI MTD in the MSKCC model was not significantly different between the sub-groups.
MTD in men with intermediate-risk disease may be relevant to helping choose the appropriate radiation treatment option, with various options including brachytherapy alone, dose-escalated external beam radiotherapy alone, external beam radiotherapy with a brachytherapy boost, or the addition of ADT to external beam radiotherapy or brachytherapy. As noted in the MSKCC study sub-stratifying intermediate-risk men into favorable and unfavorable subgroups, a difference in 8-year PCSM of 0.8% vs. 4.2%, respectively, was seen in patients treated with dose-escalated external beam radiotherapy (2) . However, a recent report in a cohort that underwent brachytherapy demonstrated a smaller difference with 15-year PCSM of 0.6% for favorable and 2.2% for unfavorable intermediate-risk men (19) .
These data suggest that does-escalated external beam radiotherapy (to approximately 75-80 Gy) may still not achieve a sufficiently high dose for cure. This is especially clear when compared to the benefit that higher doses with brachytherapy alone (or as a boost) can provide for men with unfavorable risk intermediate-risk prostate cancer, who are more likely to have larger tumors as shown by this study. This hypothesis is supported by a study comparing doseescalated radiotherapy with external beam alone to doseescalation with a high-dose-rate brachytherapy boost for men with intermediate-risk disease, which showed improved disease-free survival and overall survival for brachytherapy patients (20) . Men with >50% cores positive, perineural invasion, or cT2b-c disease had a superior 5-year biochemical control of 96% when treated with a brachytherapy boost compared to 87% when treated with dose-escalated external beam radiotherapy alone. As ADT also improves outcomes in patients that tend to have larger tumors (unfavorable risk patients), ADT may in fact also be acting as an alternative way to dose escalate -by sensitizing cancer cells to radiation (21) .
Some limitations of the present study are apparent. One limitation is its retrospective nature, so selection bias may be present. Another limitation is that this is a study of a limited number of patients, which may have been too small to show the predictive power of these sub-stratification models for several pre-treatment mpMRI parameters or adverse pathologic outcomes. Alternatively, this may suggest that mpMRI may not be as useful a predictor for important clinical outcomes like PCSM, or it may suggest that and the intermediate-risk
sub-stratification models have complementary roles in predicting pathologic and clinical outcomes. Additionally, while MSKCC and ProCaRS may be able to stratify patients with intermediate-risk prostate cancer for PCSM, strong predictors of PCSM following RP include adverse pathologic outcomes like GS upgrading, seminal vesicle invasion, and ECE. The variability of these models to predict for these adverse pathologic outcomes may be due to a larger cohort being needed, or it may be due to these models being incomplete and better informed by additional pre-treatment data -perhaps mpMRI MTD. Indeed, it is plausible to even hypothesize that the pre-treatment clinical and biopsy factors sub-stratifying men into favorable/low and unfavorable/high intermediate-risk prostate cancer are really surrogates for prostate tumor volume, and this is why we see the clinical effects of radiation dose escalation (or dose effectiveness increases with ADT radiosensitization) improving clinical outcomes.
In conclusion, we demonstrated that the two recently established prognostic models for sub-stratification of intermediate-risk prostate cancer can successfully predict for pathologic MTD (both schemes). The presence of pathologic extracapsular extension (MSKCC) and percentage of prostate involved in malignancy (MSKCC) MTD is an important prognostic factor for discriminating between favorable and unfavorable intermediate-risk patients, although association with pre-treatment mpMRI MTD was only seen for the ProCaRS model.
The association of unfavorable/high intermediate-risk prostate cancer with a higher MTD may help explain why we observed greater treatment failure when using the same dose for men with unfavorable/high as compared to favorable/low intermediate-risk disease, which appears improved with the use of ADT. Further optimization of pretreatment prostate tumor volume assessment, perhaps with mpMRI or newer imaging modalities, may help improve treatment selection.
